Literatur zu

**Muskelrelaxanzien**

Ist neuromuskuläre Überwachung bei kurzwirkenden Muskelrelaxanzien noch erforderlich?

Manfred Blobner


3 Eriksson LI. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003; 98: 1037–1039


8 Savage DS, Sleigh T, Carlyle I. The emergence of ORG NC 45, 1- [2 beta,3 alpha,5 alpha,16 beta,17 beta)-3, 17-bis(acetyloxy)-2-(1-piperidinyl)-androstan-16-yl]-1-
methylpiperidinium bromide, from the pancuronium series. Br J Anaesth 1980; 52 Suppl 1: 3s–9s


15 DGAI. Verwendung von Succinylcholin – Aktualisierte Stellungnahme der DGAI. Anästh Intensivmed 2002; 43: 831

16 Taeger K. Kommentar zur aktualisierten Stellungnahme der DGAI. Anasth. Intensivmed. 2003; 44: 326


19 Viby Mogensen J, Chraemer Jorgensen B, Ording H. Residual curarization in the recovery room. Anesthesiology 1979; 50: 539–541


35 Murphy GS, Szokol JW, Marymont JH et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesthesia and Analgesia 2008; 107: 130–137

36 Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology 1997; 86: 765–771


